Bemarituzumab

Phase 3Monoclonal antibody

Amgen

Bemarituzumab is one of 134 small molecule programs targeting Esophageal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerNot yet recruiting

Renal Cell CarcinomaNot yet recruiting

Gastric CancerActive, not recruiting

BevacizumabNot yet recruiting

Esophageal CancerPhase 1

Not yet recruiting

Renal Cell CarcinomaPhase 2

Not yet recruiting

Gastric CancerPhase 3

Active, not recruiting

BevacizumabPhase 2

Not yet recruiting

Competition

Competitive Landscape

193 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 3

23 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

55 3

Taxotere

AAvyxa

Phase 3

45 4

Avastin

Roche

Phase 3

11 5

Beyfortus

BeiGene

Phase 3

10 6

Elunate

Takeda

Phase 3

7 7

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

19 8

Tuoyi

SSun Yat-sen University

Phase 3

18 9

Lynparza

AstraZeneca

Phase 3

5 10

Adrucil

EElorac, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Not yet recruiting

Renal Cell Carcinoma

NCT07470840

Q3 2029

Phase 1Not yet recruiting

Esophageal Cancer

NCT06978062

Q4 2030

Phase 1/2Not yet recruiting

Bevacizumab

NCT07146919

Clinical

Trials by Indication[1]

Gastric Cancer3 trials

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT05052801·547 enrolled

A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

Terminated· Amgen logo

Amgen·Phase 3·NCT05111626·515 enrolled

A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).

Terminated· Amgen logo

Amgen·Preclinical·NCT05322577·72 enrolled

Esophageal Cancer2 trials

Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment

Not yet recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT06978062·27 enrolled

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer

Completed·FFive Prime Therapeutics, Inc.·Phase 1·NCT03343301·12 enrolled

Gastric/Gastroesophageal Junction Cancer1 trial

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

Completed·FFive Prime Therapeutics, Inc.·Phase 2·NCT03694522·155 enrolled

Monotherapy1 trial

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Terminated· Amgen logo

Amgen·Phase 1·NCT05267470·74 enrolled

Renal Cell Carcinoma1 trial

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07470840·27 enrolled

3 more indications

Bevacizumab1 trial

AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

Not yet recruiting·CCentre Leon Berard·Phase 1/2·NCT07146919·87 enrolled

Esophageal Adenocarcinoma1 trial

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Completed·UUniversity of Chicago·Phase 2·NCT02213289·80 enrolled

Solid Tumors1 trial

A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)

Terminated· Amgen logo

Amgen·Preclinical·NCT05325866·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Bemarituzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bemarituzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bemarituzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Amgen

Bemarituzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q3 2029

Q4 2030

Trials by Indication[1]

Gastric Cancer3 trials

Esophageal Cancer2 trials

Gastric/Gastroesophageal Junction Cancer1 trial

Monotherapy1 trial

Renal Cell Carcinoma1 trial

Bevacizumab1 trial

Esophageal Adenocarcinoma1 trial

Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News